All In Biotech

Drug Trial Radar · NCT04452955

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

An Open Label, Multicenter, Safety and Efficacy Phase 2 Study of PRL3-Zumab in Solid Tumors

Last checked: Nov 20, 2026Latest source record: Apr 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

51

Actual

Start

Dec 12, 2020

Primary completion

Dec 1, 2026

Study completion Dec 1, 2026

Sponsor

Lead sponsor
Intra-IMMUSG Pte LtdIndustry
Sponsor type
Industry
Collaborators
Parexel
First posted
Jul 1, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor.

Conditions

  • Solid Tumor

Interventions

  • PRL3-zumabBiological

    Starting dose of 6 mg/kg will be administered as IV infusion over 60 minutes every 2 weeks (±2 days)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression free survival (PFS)Time frame: From first dose of study drug until disease progression or end of treatment, whichever comes first

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • HonorHealth Research

    Scottsdale, Arizona

  • St. Jude Medical Center

    Fullerton, California

  • The Angeles Clinic

    Los Angeles, California

  • Norton Healthcare

    Louisville, Kentucky

  • Comprehensive Cancer Centers of Nevada

    Las Vegas, Nevada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.